H.C. Wainwright raised the firm’s price target on Syndax (SNDX) to $51 from $49 and keeps a Buy rating on the shares after Revuforj received FDA approval for acute leukemia with KMT2A translocation.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX: